---
title: Samsung Biologics vs Syngene International
slug_a: samsungbiologics
slug_b: syngeneintl
site: cdmo
review_signal_gate: closed
canonical_path: /compare/samsungbiologics/syngeneintl
generated_by: BioBM Editorial AI
---

# Samsung Biologics vs Syngene International

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Samsung Biologics (samsungbiologics) is listed for cdmo. Leading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.

Services: 23. Modalities: 5. Indications: 1. Locations: 8. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (23).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Syngene International (syngeneintl) is listed for both. Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

Services: 100. Modalities: 10. Indications: 14. Locations: 3. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (100).

Review summary: Review summary withheld until site-level review gate opens.